C-reactive protein and interleukin-6 are decreased in transgenic sickle cell mice fed a high protein diet

Journal of Nutrition

Volumn 138, Issue 6, 2008, Pages 1148-1152

  Archer, David R ^a   Stiles, Jonathan K ^b   Newman, Gale W ^b   Quarshie, Alexander ^b   Hsu, Lewis L ^c   Sayavongsa, Phouyong ^b   Perry, Jennifer ^a   Jackson, Elizabeth M ^b   Hibbert, Jacqueline M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIETARY INTAKE; HYPERMETABOLISM; INFLAMMATION; MOUSE; NONHUMAN; NUTRITIONAL ASSESSMENT; PROTEIN DIET; REAL TIME POLYMERASE CHAIN REACTION; SICKLE CELL; SICKLE CELL ANEMIA; STEADY STATE; WEIGHT GAIN;

MUS;

EID: 44449171416     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/138.6.1148     Document Type: Article

References (43)

1. Salman EK, Haymond MW, Bayne E, Sager BK, Wiisanen A, Pitel P, Darmaun D. Protein and energy metabolism in prepubertal children with sickle cell anemia. Pediatr Res. 1996;40:34-40.
2. Hibbert JM, Hsu LL, Bhathena SJ, Irune I, Sarfo B, Creary MS, Gee BE, Mohamed AI, Buchanan ID, et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. Exp Biol Med (Maywood). 2005;230:68-74.
3. Singhal A, Davies P, Sahota A, Thomas PW, Serjeant GR. Resting metabolic rate in homozygous sickle cell disease. Am J Clin Nutr. 1993;57:32-4.
4. Badaloo A, Jackson AA, Jahoor F. Whole body protein turnover and resting metabolic rate in homozygous sickle cell disease. Clin Sci. 1989;77:93-7.
5. Jackson AA, Landman JP, Stevens MCG, Serjeant GR. Urea kinetics in adults with homozygous sickle cell disease. Eur J Clin Nutr. 1988;42:491-6.
6. Hibbert JM, Forrester T, Jackson AA. Urea kinetics: comparison of oral and intravenous dose regimens. Eur J Clin Nutr. 1992;46:405-9.
7. Reed JD, Redding-Lallinger R, Orringer EP. Nutrition and sickle cell disease. Am J Hematol. 1987;24:441-55.
8. Singhal A, Parker S, Linsell L, Serjeant G. Energy intake and resting metabolic rate in preschool Jamaican children with homozygous sickle cell disease. Am J Clin Nutr. 2002;75:1093-7.
9. Schnog JJ, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, Muskiet FA. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371-5.
10. Singhal A, Thomas P, Cook R, Wierenga K, Serjeant G. Delayed adolescent growth in homozygous sickle cell disease. Arch Dis Child. 1994;71:404-8.
11. Singhal A, Doherty JF, Raynes JG, McAdam KP, Thomas PW, Serjeant BE, Serjeant GR. Is there an acute-phase response in steady-state sickle cell disease? Lancet. 1993;341:651-3.
12. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol. 1998;61:49-54.
13. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287:H293-301 10.1152/ajpheart.01150.2003.
14. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83-9.
15. Stuart J, Stone PCW, Akinola NO, Gallimore JR, Pepys MB. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J Clin Pathol. 1994;47:166-9.
16. Hibbert JM, Creary MS, Gee BE, Buchanan ID, Quarshie A, Hsu LL. Erythropoiesis and myocardial energy requirements contribute to the hypermetabolism of childhood sickle cell anemia. J Pediatr Gastroenterol Nutr. 2006;43:680-7.
17. Matthys P, Billiau A. Cytokines and cachexia. Nutrition. 1997;13:763-70.
18. Silva CM, Viana MB. Growth deficits in children with sickle cell disease. Arch Med Res. 2002;33:308-12.
19. Serjeant GR, Singhal A, Hambleton IR. Sickle cell disease and age at menarche in Jamaican girls: observations from a cohort study. Arch Dis Child. 2001;85:375-8.
20. Hasanato RM. Zinc and antioxidant vitamin deficiency in patients with severe sickle cell anemia. Ann Saudi Med. 2006;26:17-21.
21. Heyman MB, Vichinsky E, Katz R, Gaffield B, Hurst D, Castillo R, Chiu D, Kleman K, Ammann AJ, et al. Growth retardation in sickle cell disease treated by nutritional support. Lancet. 1985;1:903-6.
22. Paszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876-8.
23. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 2001;98:15215-20.
24. Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC, Hebbel RP, Vercellotti GM. Transgenic sickle mice have vascular inflammation. Blood. 2003;101:3953-9.
25. Pritchard KA Jr, Ou J, Ou Z, Shi Y, Franciosi JP, Signorino P, Kaul S, Ackland-Berglund C, Witte K, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2004;286:L705-14.
26. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114:1136-45.
27. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41:1771-80.
28. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109:3088-98.
29. Hsu L, Diwan B, Ward JM, Noguchi CT. Pathology of "Berkeley" sickle-cell mice includes gallstones and priapism. Blood. 2006;107:3414-5.
30. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS. Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood. 2006;107:1651-8.
31. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-51.
32. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-7.
33. Jackson AA. Limits of adaptation to high dietary protein intakes. Eur J Clin Nutr. 1999;53:S44-52.
34. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. Am J Med Sci. 1990;300:366-71.
35. Imura K, Okada A. Amino acid metabolism in pediatric patients. Nutrition. 1998;14:143-8.
36. Reid M, Badaloo A, Forrester T, Jahoor F. In vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease. Am J Physiol Endocrinol Metab. 2006;291:E73-9.
37. Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 2002;24:374-9.
38. Francis RB Jr, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc. 1992;84:611-5.
39. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol. 2004;77:323-8.
40. Morris CR. New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy. Treat Respir Med. 2006;5:31-45.
41. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81-90.
42. Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, Styles LA. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 2000;111:498-500 .
43. Styles LA, Kuypers F, Kesler K, Reiss U, Lebeau P, Nagel R, Fabry M. Arginine therapy does not benefit children with sickle cell anemia: results of the comprehensive sickle cell center multi-center study. 35th convention of National Sickle Cell Disease Program and the Sickle Cell Disease Association of America, Sept 2007; Washington, DC, abstract no. 114.